Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup, TenAces.
TenAces will utilize AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to enhance targeted protein degradation.
Molecular glues are protein-binding small molecules that change two protein...